Publications by authors named "Clemence Blaize"
Fundam Clin Pharmacol
August 2024
Article Synopsis
- This study reviews the risk of arterial hypertension in patients using poly (ADP-ribose) polymerase inhibitors (PARPi) based on data from randomized controlled trials (RCTs).
- In analyzing 41 RCTs with over 15,000 patients, it was found that while olaparib was associated with a lower hypertension risk compared to placebo, niraparib significantly increased the risk of hypertension. The incidence was reported at about 19.87%.
- The findings highlight the importance of monitoring for hypertension when using niraparib to ensure the therapeutic benefits are maintained, especially given that 66% of hypertension cases in real life were serious.
